All posts by imreal

Gateway Genomics Surpasses 200,000 SneakPeek Early Gender DNA Tests Sold with the Acceleration of At-Home Kit Purchases


SneakPeek Early Gender At-Home DNA Test

SneakPeek Early Gender At-Home DNA Test

In the current environment of physical distancing, SneakPeek At-Home provides families with an alternative way to learn their baby’s gender that’s perfectly suited to staying home and staying safe.

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, reached 200,000 SneakPeek Early Gender DNA Tests sold in March, just months after attaining the 150,000-test landmark in late 2019.

“SneakPeek was launched as an ecommerce product, where a mom could order her kit online, collect a DNA sample from her home, mail it back for analysis at our lab, and receive her emailed boy-or-girl result, all in days,” says Gateway Genomics CEO, Chris Jacob. “Direct-to-consumer is where the expertise of our company lies, and over the years we’ve optimized our product to be convenient and easy to use right at home. In the current environment of physical distancing, we’re grateful to be able to provide families with an alternative solution to learn the gender of their babies that’s perfectly suited to staying home and staying safe.”

The SneakPeek Test by Gateway Genomics analyzes cell-free fetal DNA found in mom’s blood to return just one answer – the gender of her unborn baby. This enables the test to use a very small amount of blood that can be collected at home. Results are emailed as fast as 72 hours after an order is placed online, with 99.1% accuracy for women who are at least 8 weeks into pregnancy, based on peer-reviewed studies.

“We understand this is a difficult situation and time, and not all families will want to or be able to visit their doctors to learn the fetal sex of their baby,” continues Mr. Jacob. “Our goal is to ensure that DNA-based prenatal information is accessible and affordable. In these uncertain times, we’re proud to deliver a product that gives parents the information they need to make plans, under their control. The SneakPeek Early Gender DNA Test provides a laboratory-proven at-home option to learn a baby’s gender and share the joy with family and friends.”

This year, Gateway Genomics was ranked #236 in the 38th annual Inc. 500|5000 list of fastest-growing private companies, #23 in the Health sector, in recognition of achieving 1,786% revenue growth in the last three years. The company’s principal product, SneakPeek, is an easy-to-use DNA test that lets parents know the gender of their babies as early as 8 weeks into pregnancy, with 99.1% accuracy.

About Gateway Genomics

Gateway Genomics is a personal genomics company with the mission to develop leading-edge genetic tests that give families a new level of understanding about their future children. Since inception, more than 200,000 SneakPeek Early Gender DNA tests have been provided to help new parents bond with their babies, make plans, and connect with friends and family around them. Gateway Genomics is located in La Jolla, CA.

Share article on social media or email:

Bravrr Launches Novel Assessment Tool for Bruxism Disorders


More than 90% of bruxism patients go undiagnosed

Bravrr, a company dedicated to providing wearable diagnostic and digital therapeutic technologies to clinicians and patients, has launched BruxRelief, an innovative assessment tool for bruxism disorders.

The BruxRelief system is a wearable headband incorporating patent-pending sensors that connect with an app on a dental patient’s smartphone. These sensors detect the activity of the temporalis muscle caused by the clenching and grinding behaviors associated with bruxism. “More than 90% of bruxism patients go undiagnosed,” said Brock Predovich, CEO and founder of Bravrr. “Bruxism can lead to deterioration of the dentition, TMJ dysfunction, migraines, vertigo, tinnitus, and localized pain in the neck, jaw, or teeth.”

“The way in which bruxism is currently diagnosed is less than ideal. Rather than being able to intervene early, dentists must wait to observe wear on a patient’s teeth. At this point, the damage is already done,” said Dr. Chris Salierno. In his role as Chief Development Officer for Cellerant Consulting Group, Dr. Salierno has advised Bravrr on the clinical development of the BruxRelief system from early stages to launch.

A typical BruxRelief assessment involves the patient wearing the headband for three nights in the comfort of their own home. The data is recorded to the smartphone app providing both the patient and clinician with a clear picture of the frequency and duration of unconscious temporalis muscle contractions associated with bruxism behavior.

“Patients rarely acknowledge that they have a bruxism disorder as they are not acutely aware of their clenching/grinding behavior,” added Dr. Salierno. “BruxRelief provides the dentist with objective data to demonstrate to the patient the presence of a parafunctional condition. Having this data makes it easier for the patient to accept the need for a nightguard appliance to minimize further damage caused by bruxism.”

Future iterations of the device will seek to include a biofeedback mechanism. Mr. Predovich adds, “the cognitive-behavioral training and muscle reeducation possible with a biofeedback loop can play a huge role in reducing or even eliminating the pain associated with this undesired behavior. While assessment is the first step, Bravrr embraces the opportunity to help patients better control their parafunctional habits, leading to an improved quality of life.”

For more information on the BruxRelief assessment device, please visit http://www.bruxrelief.com. To learn more about Bravrr, visit http://www.bravrr.com.

About Bravrr

Founded and led by Brock Predovich, an individual who personally suffered from a bruxism disorder, Bravrr Inc. is committed to conceiving, developing, manufacturing, and marketing wearable diagnostic and digital therapeutic technologies for clinicians and patients. The company is located in Cañon City, Colorado.

Bravrr Press Contact

Mr. Brock Predovich, CEO Bravrr Inc. Phone: 720-258-6699 info@bravrr.com http://www.bravrr.com

About Cellerant Consulting Group

Founded and led by CEO Lou Shuman, DMD, CAGS Cellerant provides strategic dental market insights, clinical expertise, and implementation resources to accelerate growth for client dental companies. Cellerant services include product development, accelerated market awareness due to intimate relationships with the media community, new concept incubation, clinical product evaluation, manufacturing, seed funding, continuing education program development and CE sponsorship, 510k support, strategic branding and marketing, corporate social media, website development and online marketing resources, lead generation and dental media relations management. As an orthodontist and former owner of a 10-doctor multi-specialty private group practice, Dr. Shuman guides clients to develop offerings that connect with and engage dental customers on a relationship level that provides sustained differentiation. Cellerant operates under a unique model that merges leading voices in clinical product evaluation and strategic partner companies to provide a menu of services from one easily accessible network.

Cellerant Press Contact

Thais Carter Cellerant Consulting Group Phone: 800-884-5707 ext. 108 info@cellerantconsulting.com http://www.cellerantconsulting.com

Share article on social media or email:

TorkLaw Now Taking COVID-19 Business Interruption Insurance Denial Cases


TorkLaw is now taking COVID-19 Business Interruption Insurance Claim Denial cases on behalf of business owners or operators who have been adversely impacted by COVID-19.

“Business owners and operators have reported insurance companies are denying valid COVID-19-related business interruption policy claims,” said TorkLaw founder Reza Torkzadeh. “My firm is ready to help anyone dealing with COVID-19 business interruption or bad faith insurance practices.”

TorkLaw is now accepting COVID-19 Business Interruption Insurance Claim Denial cases on behalf of businesses who have had valid insurance claims denied by their insurance companies.

Many States and local governments have mandated non-essential businesses to close down, preventing businesses from operating. In addition, many areas have restrictions to limit crowd size and halt businesses such as restaurants and bars. Owners and operators of many such businesses are filing claims against their business interruption insurance to cover their losses.

“Business owners and operators have reported insurance companies are denying valid COVID-19-related business interruption policy claims,” said TorkLaw founder Reza Torkzadeh. “My firm is ready to help anyone dealing with COVID-19 business interruption or bad faith insurance practices.”

Commercial business insurance policyholders may have valid claims for losses related to the coronavirus pandemic if their policy’s declaration page for coverage language such as:

  • Business Interruption
  • Business Disruption
  • Contingent Business Interruption
  • Civil Authority
  • Government-ordered closure
  • Lost or Restricted Access
  • Loss of Ingress / Egress
  • All Risk
  • Open Perils
  • Special Perils

Effective immediately, TorkLaw is welcoming calls from any business owners or operators who have been impacted by COVID-19, or who feel that their business interruption insurance claim was denied unfairly. Interested parties can visit https://bit.ly/torklaw-covid19 for more information, or call 888.845.9696 for a free, no-obligation consultation.

Share article on social media or email:

CC Wellness converts production to Hand Sanitizers as top priority for public health


CC Wellness is passionate about health and wellness, and we believe that a healthy body leads to a healthier mind. That’s why during this coronavirus crisis, we’re producing 800,000 bottles every month, contributing to healthy bodies while quelling fears and anxiety, one bottle at a time,” says Catherine Corsaro, Director of Marketing & Product Development at CC Wellness, the parent company of Muse Intimacy.

With drug stores unable to keep germ-killing products on the shelf, CC Wellness has begun ramping up their Muse Intimacy Hand Sanitizer which is expected to reach 6,400,000 ounces by the end of April. CC Wellness specializes in the development and production of pharmaceutical-grade OTC’s (over the counter) and Class 2 medical devices, and their intimate wellness brand #LubeLife is a best seller with a number one ranking on Amazon.com.

“So much feels out of control with the spread of the coronavirus, but there is one thing that every individual has control over – and that’s making sure our hands are germ-free! That’s something our wellness brand can help with,” Corsaro says. “Our goal is to help everyday people who are looking to slow the spread of the virus, but can’t find hand sanitizer on the shelf at their local drug store.”

Muse Hand Sanitizer kills 99.9% of germs, including the COVID-19 bacteria, and also contains Vitamin E (Tocopheryl Acetate), which has proven antioxidant effects, enhances moisturization and strengthens the skin barrier. It comes in a simple 8oz bottle with a white and robin’s egg blue label and a snap shut no-drip cap. It’s portable, easy to use – and most importantly – can help save lives! To use hand sanitizer properly, treat it as a ‘wash,’ using a nickel-sized dollop and wetting every part of your hands and fingers, including in and around the nail beds.

Not every intimate wellness manufacturer is able to instantly produce hand sanitizer, because the high alcohol content puts it in a different licensing category, but because CC Wellness holds both an OTC license from the FDA as well as the license to purchase alcohol, they are in a unique position to meet the growing demand for hand sanitizer. CC Wellness stands ready to help combat COVID-19 nationwide with their Muse Intimacy Hand Sanitizer, which thankfully, is available for order now.

Muse Intimacy Hand Sanitizer is available now for purchase at http://www.museintimacy.com,.

About CC Wellness

At CC Wellness, consumer health and wellness has been our passion since 2003. We strive to anticipate the needs of consumers, focusing on finding solutions that make a difference with innovation and agility, bringing products to the market faster than large corporations.

With fifteen FDA clearances and product profiles spanning cosmetics, OTC and Class II medical devices, CC Wellness operates from our facility in Valencia, California, with start to finish in-house product development, registration and production. Using USDA approved organic products, cruelty-free practices and 100% recyclable packaging, we strive to do our part to build a more sustainable, clean future while creating the highest quality products in a socially and environmentally conscious manner. CC Wellness consistently achieves top three brand positioning on Amazon in its class and is widely recognized as both a pioneer and a leader in the field of health and intimate wellness

Share article on social media or email:

Operative IQ Assists First Responders with Operational Readiness During COVID-1


Operative IQ’s Inventory and Asset management solutions help first responders manage critical medical supply inventory and equipment efficiently in real-time amidst the Coronavirus Pandemic.

First Responders must regularly perform vehicle checks, inventory counts, expiration date audits, restock orders and verify equipment location and condition. Operative IQ is aiding agency readiness by standardizing processes and capturing information to assist in decision making that will ensure the availability of needed supplies and equipment.

Using an integrated Operative IQ check sheet, front-line providers capture availability and usage data which is used to calculate ideal stocking quantity for each item in any given supply room. The Manage Inventory Levels tool in Operative IQ analyzes average weekly usage along with demand variability for each item to calculate suggested stocking parameters. With increased national supply demand and longer order lead times, this tool enables providers to accurately forecast supply needs to stay ahead of the ordering curve.

With ideal stock levels and on-hand inventory counts established, Operative IQ assists agencies in ordering needed supplies by generating a draft purchase requisition for review. Orders can be submitted to suppliers in a variety of ways, but electronic processing of approved POs through Operative IQ’s integrated suppliers saves time, improves accountability and reduces errors. Integrated suppliers include Bound Tree Medical, Life-Assist, Moore Medical, McKesson Medical, Medline, Grainger and Office Depot.

Status Boards and reports provide first responders quick access to real-time supply levels, orders and status updates. EMS managers analyze detailed views of available inventory, expiration dates, supply usage and trends through Operative IQ to make sound decisions. Streaming access to this live, critical data allows agencies to proactively manage scarce resources in this rapidly evolving public health situation.

From Florida to Washington State, departments are currently taking advantage of Operative IQ’s RFID Automation Technology to quickly and accurately reconcile supply room on-hand inventory counts. Automation of this manual process saves time and improves inventory accuracy while freeing up field staff to provide medical care.

RFID handheld and fixed readers capture live inventory counts and expiration dates within minutes allowing logistics to restock needed supplies at outlying stations keeping them service ready. Operative IQ is also helping providers account for critical assets and life-saving equipment in the field. Crew can account for assets using an electronic check sheet on any device and Operative IQ’s RFID handheld reader takes it a step further by automating the verification of assigned assets on each unit within minutes through a quick scan of the truck.

In this public health crisis, Operative IQ is being used by thousands of public safety professionals on the front line and behind the scenes to ensure our first responders remain ready to serve.

EMS Technology Solutions offers cutting edge, affordable operations management software and products designed with First Responders in mind. Operative IQ Operations Management Software offers modules that include: Inventory Management & Asset Management, Integrated Purchasing, Fleet Maintenance, Service Desk Ticketing System and RFID Tracking. EMS Technology Solutions has won four consecutive EMS World Top Innovation Awards for its operations management software.

Share article on social media or email:

Clinically Validated Pathology-based AI Prediction of ACE2 Expression as A Predictive Biomarker of COVID-19 Mortality Rate


ACE2 mRNA level can serve as a predictive biomarker of COVID-19 mortality rate. Hospitalized COVID-19 patients can be stratified on admission based on their ACE2 mRNA levels, so that the corresponding level of care can be planned and prepared well in advance.

INTRODUCTION

As the world’s first AI-biopharma company that has discovered and publicized the precise aetiology and pathology of COVID-19[1], we are committed to the non-profit dissemination of our COVID-19 discoveries and the public validation of our COVID-19 clinical predictions.

The SARS-CoV-2-mediated post-entry suppression of ACE2 mRNA expression in host cells is one of our contrarian pathology-based clinical predictions, because it appears to be self-conflicting for SARS-CoV-2 to bind ACE2 via S to enable viral entry on the one hand[2], and to suppress ACE2 expression to enhance viral replication on the other hand[1]:

“After entry, SARS-CoV-2 hijacks the PI3K signaling of ACE2-expressing host cells to drive viral replication. Furthermore, SARS-CoV-2 enhances the activation of the distal promoters of the ACE2 gene in the host cells, which further suppresses the ACE2 expression in the host cells and disrupts the normal homeostatic functions of the host cells.”[1]

“The ACE2 distal promoter transcript (DPT) is an evolutionarily conserved binding motif of ACE2 inhibitors, whereas the ACE2 proximal promoter transcript (PPT) is an evolutionarily conserved binding motif of ACE2 enhancers[5]. The DPT/PPT ratio is tissue-specific such that the DPT is significantly more than the PPT in the lung (>49-fold), whereas the PPT is significantly more than the DPT in the kidney, brain, and heart (>20-fold)[6]. It is unusual that the ACE2 DPT/PPT ratio, rather than the ACE2 genotype, determines ACE2 transcript levels.” [1]

We also shared the further pathology-based clinical prediction that ACE2 deficiency is a core causal co-driver of COVID-19 clinical outcomes[3]:

“The clinical outcomes of COVID-19 are driven by the tissue-specific and patient-specific co-development of ACE2-deficiency-induced injury and innate-adaptive-imbalance-induced lymphocytopenia.” [1]

“Therefore, lungs are selectively vulnerable to ACE2 deficiencies induced by COVID-19, and lung injuries are the predominant clinical features of COVID-19.” [1]

When that pathology-based prospective prediction was first announced to the public on March 7, 2020[3], it was also contrarian to the mainstream view that (i) populations with lower baseline ACE2 expression level are less prone to SARS-CoV-2 entry and infection, and (ii) East Asians are more vulnerable to COVID-19 than Europeans/Americans because the human genomic data published on February 24, 2020, show that East Asians have much higher allele frequencies in most of the gain-of-function eQTL variants of ACE2 (Figure 1).

DATA VALIDATION

Those two contrarian prospective clinical predictions can be validated by analyzing the relationship between population-specific ACE2 genome data and population-specific COVID-19 mortality data.

As of April 4, 2020, there are 13 countries categorized into four region-specific populations following the definitions in Figure 1—Chinese (CHN), Non-Chinese East Asians (EAS), Europeans (EUR) and AdMixed Americans (AMR)—with each country having reported more than 10,000 confirmed COVID-19 cases (Table 1).

As of April 4, 2020, the total number of confirmed COVID-19 deaths per million population in those 13 countries are presented in Table 2.

Furthermore, the population-specific allele frequencies of 11 common eQTL variants associated with high expression of ACE2 in tissues are presented in Table 3.

Now we can start analyzing the relationship between population-specific ACE2 genome variants and population-specific COVID-19 mortality rates (Table 4).

Both the population covariance (-6.46) and the Pearson correlation (-0.88) clearly indicate that the population-specific ACE2 mRNA levels have a strong negative relationship with the population-specific COVID-19 mortality rates.

In other words, populations with higher baseline ACE2 mRNA levels (e.g., East Asians) would be less prone to the ACE2-deficiency-driven development of critical COVID-19 clinical outcomes, whereas populations with lower baseline ACE2 mRNA levels (e.g., Europeans) would be more prone to the ACE2-deficiency-driven development of critical COVID-19 clinical outcomes.

Therefore, the real-world data have validated our contrarian pathology-based clinical prediction that ACE2 deficiency is a positive driver of COVID-19 clinical outcomes[3], and thus invalidated the mainstream belief that ACE2 deficiency is a negative driver of COVID-19 clinical outcomes.

The real-world data further demonstrate that AI-based disease modelling and clinical predictions can deliver much better predictive power and explanatory power than conventional approaches for novel diseases with limited clinical data and short response timeframes.

PREDICTIVE BIOMARKER

Based on our pathology-based clinical predictions which are validated both by the real-world data as above and by the ex vivo data in human organoids[7], we thus further propose that ACE2 mRNA level can serve as a predictive biomarker of COVID-19 mortality rate, and even a surrogate biomarker of COVID-19 clinical progression.

Hospitalized COVID-19 patients can be stratified on admission based on their ACE2 mRNA levels, so that the corresponding level of care can be prepared well in advance.

Suspected COVID-19 patients can be stratified if they can receive the test of ACE2 mRNA levels at the same time when they receive the test of SARS-CoV-2 RNA levels.

TREATMENT PRIORITY

Contrary to the mainstream belief, COVID-19 would have a much more rapid and severe progression in Americans/Europeans compared with East Asians, because Americans/Europeans have much lower baseline ACE2 expression than East Asians due to their much lower allele frequencies in most of the gain-of-function eQTL variants of ACE2[4].

As our aetiology and pathology show that COVID-19 suppresses ACE2 expression for viral replication, Americans/Europeans with much lower baseline ACE2 expressions are much more prone to developing critical clinical outcomes than East Asians.

Therefore, on top of increasing the supply of masks and ventilators, it is much more important and urgent for European and American countries to prioritize the discovery and development of effective and scalable treatments for critically ill patients than for Asian countries.

Critically ill COVID-19 patient population has a 61.5% mortality rate[8] with sepsis (100%), respiratory failure (98%), and ARDS (93%) as the top 3 clinical outcomes of non-survivors[9], and there will be more critically ill patients of younger age groups in European and American countries due to the population-specific lower baseline ACE2 expression levels.

It is equally essential to discover scalable treatments that are cost-effective and globally available to reduce the mortality rate of COVID-19 in various European and American countries of different infection control capabilities.

REFERENCES

1.    Lovetrue, B. The AI-Discovered Aetiology of COVID-19 and Rationale of the Irinotecan+Etoposide Combination Therapy for Critically Ill COVID-19 Patients. (2020). doi:10.20944/PREPRINTS202003.0341.V1

2.    Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80-. ). 367, 1260–1263 (2020).

3.    Demiurge AI Discovers the Complete Aetiology of COVID-19 and the Optimal Treatment Strategy for COVID-19. Available at: http://www.prweb.com/releases/demiurge_ai_discovers_the_complete_aetiology_of_covid_19_and_the_optimal_treatment_strategy_for_covid_19/prweb16966447.htm. (Accessed: 1st April 2020)

4.    Cao, Y. et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 6, 4–7 (2020).

5.    COVID-19 Map – Johns Hopkins Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/map.html. (Accessed: 1st April 2020)

6.    Coronavirus deaths: The stark differences in countries’ case fatality rates, explained – Vox. Available at: https://www.vox.com/2020/4/1/21203198/coronavirus-deaths-us-italy-china-south-korea. (Accessed: 2nd April 2020)

7.    Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A. & Wimmer, R. A. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. (2020). doi:10.1016/j.cell.2020.04.004

8.    Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2600, 1–7 (2020).

9.    Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan , China : a retrospective cohort study. Lancet 6736, 1–9 (2020).

About Demiurge Technologies

Demiurge Technologies is a research-based AI-biopharmaceutical company that transforms publicly available life science data into precise disease models in areas with unmet medical needs. The company pioneers a self-correcting scientific approach that validates disease models with the accuracy of AI-based predictions of phase 3 clinical trial outcomes. The company also pioneers a self-sustaining business that commercializes disease models by accelerating the AI-based discovery and development of innovative medicines. Demiurge started in 2016 with headquarters in Switzerland.

AI has been an emerging powerful approach to deeper disease understanding and faster drug discovery, yet it must be put to the most rigorous test to prove its worth under public scrutiny. Demiurge has predicted the outcomes of more than 90 phase 3 clinical trials across multiple therapeutic areas and achieved more than 80% accuracy. Furthermore, we have been inviting the public to witness our future predictions of clinical trial outcomes on Twitter (@DemiurgeTech).

Therefore, we officially put forward AI-based discoveries of the precise aetiology and pathology of COVID-19 and the candidate treatments for COVID-19 as scientific hypotheses only and invite the world to validate their potential to solve the unprecedented global crisis posed by COVID-19.

Demiurge urges everyone to refrain from believing in the efficacy and safety of any COVID-19 candidate treatments before any clinical data come in.

Disclaimer

This material is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. These statements are not guarantees of future performance, condition or results. Figures and graphs in this presentation are for illustration only and are may not match the actual scale. Actual results may differ materially from those in the forward‐looking statements as a result of a number of factors. Demiurge Technologies AG (“Demiurge”) undertakes no duty or obligation to publicly update or revise the forward‐looking statements or other information contained in this document. You should not view information related to the past performance of Demiurge or its affiliated funds or information about the market, as indicative of future results, the achievement of which cannot be assured. While some information used in this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Amounts and percentages may reflect rounding adjustments and consequently, totals may not appear to sum.



How To Save Car Insurance Money


News Image

“Drivers can get better car insurance rates if they become safe drivers and make smart coverage selections.”, said Russell Rabichev, Marketing Director of Internet Marketing Company.

Given the current pandemic and economic crisis, it is important to manage our finances and start looking for better prices for essential services. Insurance expenses can rise to several thousand dollars per year. It all depends on several factors, including the model of the vehicle, driving experience and history, coverage limits, annual mileage and so on. Drivers can get better rates if they:


  • Look for discounts. The auto insurance market provides a high number of discounts. However, each company grants them after meeting certain demands. Ask the current carrier for a list of discounts and check for how many the requirements are met. The most common discounts include affinity discount, no-claims discount, safety gear discount, and low-mileage discount.
  • Improve credit score. Having an Excellent FICO credit score will also increase the insurability score. Companies place more trust into people who have proven that they can manage their payments. Ask for credit score reports first and check if everything is fine. If things are not that bright, look for ways of repairing the score, like using balance transfer credit cards.
  • Bundle policies and plans under the same contract. In many cases, signing for home and auto insurance with the same company will help drivers get a generous discount. Also, providing coverage for multiple vehicles from the same company will also grant access to a discount.
  • Adjust deductible limits. By increasing the deductible levels, drivers assume more financial responsibility. When filing a claim, clients pay first the sum of money agreed upon, then the company covers the rest. Selecting a high deductible will lower the premiums.
  • Park the car in a garage. Insurance companies usually provide lower premiums to those that keep their car in a garage. Using a garage has multiple advantages. Car theft becomes less probable. Another advantage is the lower chance for your vehicle to be damaged by severe weather, vandalism or rioters.
  • Keep a clean driving record. Clients can qualify for a good driver discount if they keep a clean driving record for 3-5 years. That means no claims or traffic violations. The discount ranges from 10 to 20 percent.
  • Keep a good credit score. Persons with average or poor credit scores pay more than those with an excellent score. There are several ways to improve credit score, including taking a short-term loan from a Credit Union.
  • Drive fewer miles. People who retire, use mass public transportation or carpooling should consider asking for low-mileage discounts.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

For more information, please visit http://compare-autoinsurance.org.

Share article on social media or email:

In The Midst of a Pandemic, The North Carolina Textile Industry Is Banding Together


News Image

In the midst of crisis, the entire NC textile industry is banding together to help our healthcare industry. Nufabrx®, a proprietary biomaterial company that seamlessly embeds active ingredients including vitamins, supplements and medications into fabrics, in partnership with Bossong Medical and Manufacturing Solutions Center, has shifted production for a new line of reusable copper medical masks called TheraMasks. These masks are powered by CuTEC copper, a material that is known to be naturally antibacterial.

Founder and CEO Jordan Schindler decided to quickly retool a textile product to create a reusable face mask. “Tired of feeling helpless on the sidelines, we wanted to do something that would make a difference. With our Nufabrx® technology, Bossong Medical and Manufacturing Solutions Center, everyone has linked arms and committed to help in this crisis. TheraMasks is the first-of-its-kind, reusable, CuTEC copper powered mask that lasts up to 30 washes. Already overwhelmed by inquiries, we will be prioritizing distribution to healthcare workers and first responders,” states Schindler. The products are not only beneficial to medical facilities but also to nursing homes, home care attendants, senior communities and more. They are currently being used by hospitals, NY police and fire departments, Catawba County EMS, police, fire and county officials. We are sending them out overnight delivery as quickly as we can make them.

Copper has been shown to be a natural deterrent on bacterial growth. These medical masks are designed to help reduce the spread of germs through the natural benefits of copper; the fabric also creates a healthier environment for the wearer by reducing facial contamination. The products are durable enough to be machine washed and dried, or by hand with hot water. TheraMasks are environmentally friendly, and are not intended to be thrown away daily like disposable masks. Products have been tested for antibacterial (AATCC 100) and air permeability, and all data is available online. Additional testing is underway and all data will be shared with the public as soon as it is available. Products can be purchased online at http://www.TheraMasks.com or in bulk by emailing sales@theramasks.com (while supplies last).

Achieving overall health and wellness is simplified by using any Nufabrx® product, as a result of replacing the hassle and cost of using medications, patches or creams. The materials are specifically designed for comfort and breathability, providing a close fit and ease-of-wear, while simultaneously delivering a controlled dose of medicine to the problem area. Developed in tandem with Department of Defense and MIT grant funding, this patented technology allows ingredients like capsaicin, a natural pain reducing ingredient, to be delivered directly through fabric. This technology is rolling out to Walmart nationwide in early April.

About Nufabrx® and TheraMasks

Founded in 2011, Nufabrx® was created by Founder Jordan Schindler after discovering his pillowcase was contributing to his acne. Teaming up with MIT scientists, Jordan spent seven years developing proprietary technology to embed active ingredients into clothing to make medicinal application easier and more efficient. As a way to help our healthcare workers, reusable copper medical masks were a natural transition; TheraMasks was founded as a division of nufabrx. For more information visit http://www.Nufabrx.com and http://www.Theramasks.com.

About Bossong Medical

Bossong Medical is committed to being a world class designer and manufacturer of innovative medical textile products made in the USA for the global market. Bossong Medical was founded to design, manufacture and distribute innovative medical textile products. Bossong Medical’s competitive advantage is providing compression therapy products that are of world class quality utilizing the guidelines of ISO 13485 certification and FDA registration for Class I and Class II medical devices. http://www.bossongmedical.com

About the Manufacturing Solutions Center

The Manufacturing Solutions Center was established 27 years ago to transition hosiery workers from mechanical to electronic machines. Today, companies are hiring computer designers, software engineers, and people trained to program and operate the increasingly complex knitting machines. The Manufacturing Solutions Center specializes in applied research and development, prototyping, testing, domestic sourcing, and training for 21st-century textile jobs. https://www.manufacturingsolutionscenter.org/

Share article on social media or email:

Juniper Communities takes proactive approach to testing residents and staff for COVID-19 to limit illness and deaths in seniors housing communities


Juniper Communities, a national owner-operator of seniors housing communities announced it will begin full testing of consenting residents and associates in its communities as a proactive measure to further protect chronically ill older adults from the effects of COVID-19. Testing has begun as of April 2, 2020 and will be completed across most Juniper communities as quickly as possible.

“We care for the most frail and susceptible population. Senior living communities are the first line of defense for 3 million citizens most at risk for complications and even death from this virus. They and their families rely on senior living to keep them healthy and safe,” said Lynne Katzmann, Juniper’s CEO and founder. Staff wellbeing is also a primary concern. “Our associates come to work every day dedicated to providing care to the residents, and we want to minimize the risk to them and those they care for.”

The CDC released information yesterday indicating that the virus has graver impact on older adults with the chronic conditions typically found in seniors’ housing residents. The data suggest 8 out of 10 deaths reported in the U.S. have been in adults 65 and older. More concerning to senior living, 31-70% of COVID-19-positive patients aged 85+ require hospitalization, while people ages 65-84 are also at risk of needing hospital care (31-59% of this age group). Senior living communities focus primarily on these at-risk ages. Katzmann stated, “Hospitals are clearly reaching their capacity. We hope to do our part with this initiative to flatten the curve and prevent new infections with full testing across our communities in New Jersey, Pennsylvania, and Colorado.”

Katzmann said the company’s testing initiative is based on the need to have actionable data to build a comprehensive and proactive plan. She noted Juniper has procured the tests through private/commercial vendors using CDC-qualified reagents and operating under the FDA’s Emergency Use Authorization. “We are not taking needed tests away from state health organizations, medical providers, or hospitals,” Katzmann continued. “The opening of the pipeline by the FDA is making greater testing available to everyone.”

Test results will be used to confirm symptomatic individuals for isolation, identify asymptomatic individuals for segregation, and change staffing patterns to further limit cross-contamination. “For the time being we need to dramatically reduce the number of individuals who interface daily while maintaining our high levels of care. Testing data is absolutely critical for us to put additional precautions in place—ones which appear to have had success in other countries,” Katzmann commented.

The true rate of infection within senior living communities is unknown across staff members and residents, so Juniper has made the decision to test residents and staff at their communities. Juniper believes this critical missing data point is the tool that will enable them to make decisions as to how to better manage the disease in their communities.

Juniper has been following guidelines and recommendations from the Centers for Disease Control (CDC), the Centers for Medicare/Medicaid Services (CMS) and the public health regulatory agencies for each state in which they operate. The precautions include but are not limited to: limiting access to communities to essential visitors only, screening and temperature monitoring of staff and essential visitors, enhanced infection control and cleaning procedures, social distancing and self-isolation, and in-room dining service only. Juniper monitors guidelines daily and updates practices as new information becomes available.

Juniper Communities has long been recognized as an innovator, finding solutions from outside the industry to tackle problems such as energy efficiency, purpose in life, and reducing social isolation and loneliness in elders. “We’ve successfully cared for residents through natural disasters such as Hurricane Irma without loss of life. This is the greatest challenge we have ever faced. Full testing is clearly the correct next step.” said Katzmann.

Nasal swab tests were ordered in sufficient number to test community members—residents and associates. Working in conjunction with community’s primary care providers, appropriate prescriptions were received prior to ordering of tests.

Juniper recognizes this approach has limitations. While the test is not 100% accurate, even a 70 to 80% accuracy rate should improve outcomes. There will be need for ongoing testing and surveillance, particularly with staff who go out into the wider community after their shifts.

According to Katzmann, “While we cannot predict the outcome of this pandemic, it is our hope that by extending our precautions beyond what is required we can limit exposure in our communities and continue to care for everyone at the high standard we have always maintained.”

About Juniper Communities, LLC

Juniper Communities, a leader in quality, value and innovation in long-term care, operates communities in New Jersey, Pennsylvania and Colorado that emphasize residents’ well-being, interaction and security. Our communities and approach to housing and care offers residents the opportunity to live a full life, regardless of age or health. Juniper’s innovative Connect4Life program has been proven to improve residents’ care by decreasing hospitalizations, re-hospitalizations and urgent care visits, while offering potential cost savings to public programs such as Medicare. To learn more about the many ways Juniper Communities innovates in support of our residents, please contact us at: http://www.junipercommunities.com or 973.661.8300.

Share article on social media or email:

Tran & Associates Donates Patent Services for Innovative Inventions to Stop Covid-19


how long does it take to get a patent
what does a patent do
how to apply for a patent
what is a patent for
what does patent protect
what does a patent protect
who grants patents
why get a patent
how many patents are there
how to do a patent search
how do patents work
what can be patented
how to invent something
how much do utility patents cost
how much does a patent lawyer cost
how to patent an app
how much does it cost to patent a name
how to write a patent
how long does a patent last

Tran & Associates

“Human ingenuity is the best thing we have in the fight against COVID-19.”

As the world scrambles to handle the huge wave of COVID-19 infections, urgent needs arise for medical supplies, diagnostics, and treatments. Shortages of such supplies are plaguing hospitals and care-givers, putting the lives of patients and medical professionals at risk.

Tran & Associates supports the fight against COVID-19 and encourages every-day citizens to apply their ingenuity to this global pressing problem. To support innovative solutions in this trying time, until May 5, 2020, we will provide grants covering patent preparation professional fees for up to ten best ideas that solve shortages in medical supplies, diagnostics, telemedicine, and treatments. We also recommend that inventors download and use free provisional patent application filing software at http://www.inventiv.org, a 501c3 non-profit, which can supplement inventor help resources and other publications at the USPTO. Inventors can also view “how-to” videos at our Youtube Channel that answer basic questions such as how to patent an idea, how to patent a product, how much does a patent cost, what is a patent, how to patent, and how to search patents, among others.

The COVID grant continues the Tran & Associates tradition of giving back, as we have also donated our resources to non-profits and other volunteer organizations.

For more information on the grants, please contact us at https://www.tranassoc.com/contact.html

Connect with us at

Facebook

LinkedIn

Twitter

Share article on social media or email: